Pharming Group N.V. (PHGUF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 225.49 Million USD | 42.56% |
| 2022 | 169.82 Million USD | 8.36% |
| 2021 | 156.72 Million EUR | 29.55% |
| 2020 | 120.97 Million EUR | 24.47% |
| 2019 | 97.18 Million EUR | 13.35% |
| 2018 | 85.74 Million EUR | 29.33% |
| 2017 | 66.29 Million EUR | 177.34% |
| 2016 | 23.9 Million EUR | 15.92% |
| 2015 | 20.62 Million EUR | 13.95% |
| 2014 | 18.09 Million EUR | 3.65% |
| 2013 | 17.45 Million EUR | -41.45% |
| 2012 | 29.82 Million EUR | 28.29% |
| 2011 | 23.24 Million EUR | -19.22% |
| 2010 | 28.77 Million EUR | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 36.12 Million EUR | -0.93% |
| 2007 | 36.46 Million EUR | 102364277831.9% |
| 2006 | 0.04 USD | -100.0% |
| 2005 | 22.32 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 65.57 Million USD | -8.35% |
| 2024 Q2 | 69.74 Million USD | 9.87% |
| 2024 Q1 | 63.48 Million USD | -6.2% |
| 2023 FY | 242.1 Million USD | 42.56% |
| 2023 Q4 | 67.68 Million USD | 19.88% |
| 2023 Q1 | 52.12 Million USD | -10.93% |
| 2023 Q2 | 43.87 Million USD | -15.84% |
| 2023 Q3 | 56.45 Million USD | 28.68% |
| 2022 Q1 | 38.91 Million USD | 5.85% |
| 2022 Q2 | 28.29 Million USD | -27.29% |
| 2022 Q3 | 44.09 Million USD | 55.82% |
| 2022 Q4 | 58.52 Million USD | 32.74% |
| 2022 FY | 169.82 Million USD | 8.36% |
| 2021 Q3 | 48.25 Million EUR | 39.16% |
| 2021 Q2 | 34.67 Million EUR | 8.69% |
| 2021 Q1 | 31.9 Million EUR | -20.45% |
| 2021 Q4 | 36.76 Million EUR | -23.82% |
| 2021 FY | 156.72 Million EUR | 29.55% |
| 2020 FY | 120.97 Million EUR | 24.47% |
| 2020 Q4 | 40.1 Million EUR | 39.99% |
| 2020 Q1 | 26.97 Million EUR | 0.92% |
| 2020 Q2 | 25.23 Million EUR | -6.45% |
| 2020 Q3 | 28.65 Million EUR | 13.53% |
| 2019 Q2 | 28.42 Million EUR | 44.16% |
| 2019 FY | 97.18 Million EUR | 13.35% |
| 2019 Q4 | 26.73 Million EUR | 19.83% |
| 2019 Q3 | 22.3 Million EUR | -21.53% |
| 2019 Q1 | 19.71 Million EUR | -24.14% |
| 2018 Q4 | 25.99 Million EUR | 24.99% |
| 2018 Q2 | 18.91 Million EUR | -5.64% |
| 2018 FY | 85.74 Million EUR | 29.33% |
| 2018 Q3 | 20.79 Million EUR | 9.97% |
| 2018 Q1 | 20.04 Million EUR | -16.25% |
| 2017 Q2 | 15.46 Million EUR | 46.27% |
| 2017 Q1 | 10.56 Million EUR | 45.79% |
| 2017 Q3 | 16.33 Million EUR | 5.67% |
| 2017 FY | 66.29 Million EUR | 177.34% |
| 2017 Q4 | 23.93 Million EUR | 46.47% |
| 2016 Q1 | 5.35 Million EUR | 5.7% |
| 2016 FY | 23.9 Million EUR | 15.92% |
| 2016 Q4 | 7.24 Million EUR | 18.67% |
| 2016 Q3 | 6.1 Million EUR | 17.74% |
| 2016 Q2 | 5.18 Million EUR | -3.14% |
| 2015 Q1 | 4.14 Million EUR | -4.54% |
| 2015 FY | 20.62 Million EUR | 13.95% |
| 2015 Q4 | 5.06 Million EUR | -8.18% |
| 2015 Q3 | 5.51 Million EUR | -6.33% |
| 2015 Q2 | 5.89 Million EUR | 42.3% |
| 2014 Q3 | 5.35 Million EUR | 36.78% |
| 2014 Q4 | 4.33 Million EUR | -19.05% |
| 2014 FY | 18.09 Million EUR | 3.65% |
| 2014 Q1 | 4.48 Million EUR | -10.47% |
| 2014 Q2 | 3.91 Million EUR | -12.59% |
| 2013 Q3 | 4.31 Million EUR | -3.4% |
| 2013 Q4 | 5 Million EUR | 16.03% |
| 2013 FY | 17.45 Million EUR | -41.45% |
| 2013 Q1 | 3.67 Million EUR | -57.3% |
| 2013 Q2 | 4.46 Million EUR | 21.6% |
| 2012 Q2 | 7.09 Million EUR | 4.54% |
| 2012 Q3 | 7.33 Million EUR | 3.38% |
| 2012 FY | 29.82 Million EUR | 28.29% |
| 2012 Q4 | 8.6 Million EUR | 17.23% |
| 2012 Q1 | 6.78 Million EUR | 127.39% |
| 2011 Q2 | 6.23 Million EUR | -8.18% |
| 2011 Q1 | 6.79 Million EUR | -23.4% |
| 2011 Q3 | 7.22 Million EUR | 15.86% |
| 2011 Q4 | 2.98 Million EUR | -58.69% |
| 2011 FY | 23.24 Million EUR | -19.22% |
| 2010 Q4 | 8.86 Million EUR | 38.48% |
| 2010 Q3 | 6.4 Million EUR | -1.58% |
| 2010 Q2 | 6.5 Million EUR | 0.0% |
| 2010 FY | 28.77 Million EUR | 0.0% |
| 2010 Q1 | - USD | -100.0% |
| 2009 FY | - USD | -100.0% |
| 2009 Q4 | 9.64 Million EUR | -4.02% |
| 2009 Q3 | 10.05 Million EUR | -15.38% |
| 2009 Q1 | 8.7 Million EUR | 0.0% |
| 2009 Q2 | 11.87 Million EUR | 36.45% |
| 2008 FY | 36.12 Million EUR | -0.93% |
| 2007 FY | 36.46 Million EUR | 102364277831.9% |
| 2006 FY | 0.04 USD | -100.0% |
| 2005 FY | 22.32 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -16785.26% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -4372.214% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -663.005% |
| Nascent Biotech, Inc. | 2.22 Million USD | -10012.253% |
| Rebus Holdings, Inc. | 664 Thousand USD | -33859.488% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -505.253% |
| Qrons Inc. | 643.67 Thousand USD | -34931.701% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -57782.618% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -292.568% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -54172.538% |
| Skye Bioscience, Inc. | 13.54 Million USD | -1564.441% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -159.827% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -4485.095% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -86055.369% |
| SQZ Biotechnologies Company | 85.61 Million USD | -163.366% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -7632.264% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -14913.726% |
| Mesoblast Limited | 5.9 Million USD | -3720.586% |
| Marizyme, Inc. | 19.23 Million USD | -1072.001% |
| Genus plc | 147.7 Million USD | -52.668% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -2468.459% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -10906.514% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -16708.307% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -2604.053% |
| ContraFect Corporation | 56.88 Million USD | -296.37% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -5014.715% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -15148.737% |
| IMV Inc. | 37.7 Million USD | -497.973% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -7981.081% |
| MultiCell Technologies, Inc. | 567.42 USD | -39739598.988% |
| ONE Bio Corp. | 6.44 Million USD | -3399.298% |
| Accustem Sciences Inc. | 3.74 Million USD | -5918.841% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -162.367% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -42288.554% |
| Q BioMed Inc. | 3.43 Million USD | -6461.403% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -812.365% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -8481.888% |
| Biomind Labs Inc. | 994.18 Thousand USD | -22581.058% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -127.012% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -12714.333% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -3256.512% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -11994.756% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 902064.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -1308.418% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -12187.702% |
| GB Sciences, Inc. | 1.42 Million USD | -15773.958% |
| Alpha Cognition Inc. | 9.7 Million USD | -2223.308% |
| HST Global, Inc. | 140.9 Thousand USD | -159928.246% |
| CSL Limited | 3.44 Billion USD | 93.462% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -19945.248% |
| Halberd Corporation | 74.84 Thousand USD | -301189.383% |
| Enzolytics Inc. | 2.17 Million USD | -10245.964% |
| Agentix Corp. | 1.37 Million USD | -16338.127% |
| Resverlogix Corp. | 12.71 Million USD | -1673.844% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -6076.639% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 85.296% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -21498.755% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -9276.182% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -14177.411% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -6522.39% |
| AVAX Technologies, Inc. | 7.31 Million USD | -2984.581% |
| Zenith Capital Corp. | 8.94 Million USD | -2421.425% |
| Genscript Biotech Corporation | 825.34 Million USD | 72.679% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -1294263.125% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -9083.784% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -131374.733% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -11638.784% |
| Kadimastem Ltd | 2.41 Million USD | -9256.038% |
| Helix BioMedix, Inc. | 1.97 Million USD | -11334.438% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1975.007% |
| BioStem Technologies, Inc. | 22.97 Million USD | -881.471% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -124147.734% |
| LadRx Corporation | 3.81 Million USD | -5815.618% |
| Cell Source, Inc. | 4.32 Million USD | -5113.248% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -24316.736% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -24316.736% |
| NovAccess Global Inc. | 2.46 Million USD | -9041.177% |
| Affymax, Inc. | 39.38 Million USD | -472.516% |
| Itoco Inc. | 919.14 Thousand USD | -24432.744% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -5220.174% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -20051.117% |
| Mobile Lads Corp. | 554.54 Thousand USD | -40562.271% |
| CytoDyn Inc. | 18.05 Million USD | -1148.704% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -895807.664% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -102359.583% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -15781.974% |
| SYBLEU INC | 160.87 Thousand USD | -140064.475% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -12314.718% |
| International Stem Cell Corporation | 5.27 Million USD | -4177.955% |
| Bioxytran, Inc. | 3.82 Million USD | -5802.679% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -428248.087% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1108345.165% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -521.77% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -13836.403% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -30544.234% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -7148.184% |
| Neutra Corp. | 243.82 Thousand USD | -92382.19% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1191.694% |
| PureTech Health plc | 144.59 Million USD | -55.944% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -1000.499% |
| IXICO plc | 4.7 Million USD | -4690.546% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -2463.272% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -91.503% |
| CSL Limited | 3.89 Billion USD | 94.208% |
| Cellectis S.A. | 97.32 Million USD | -131.701% |